Like for all other cancer entities, low allele fractions at post-treatment time points as well as interference of technical and biological background are hampering reliable results from ctDNA analysis for MRD detection [124] and there is an ongoing debate whether ctDNA detection could really measure up with PSA testing for MRD detection in prostate cancer [125]. The gene discussed is KLK3; the disease is prostate cancer.